文献速递肿瘤 PET/CT核素与放射性配体治疗

去势抵抗性前列腺癌中FAP与PSMA的免疫组化及PET显像表达:一项转化性初步研究

FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
PubMed 文献 · J Nucl Med · 2024-12-03

本研究在116例去势抵抗性前列腺癌(CRPC)肿瘤中评估成纤维细胞活化蛋白(FAP)表达,并以PSMA为对照。FAP在CRPC中表达显著低于PSMA,但19例PSMA阴性肿瘤中11例(58%)FAP阳性。4例临床试验患者的FAPi PET摄取低于PSMA PET,与活检样本中FAP免疫评分低于PSMA一致。作者认为FAPi PET在CRPC中的应用可能有限。

要点

  • CRPC中FAP表达显著低于PSMA(中位免疫评分14 vs 72,P<0.001)。
  • 19例PSMA阴性肿瘤中11例(58%)FAP阳性。
  • 4例患者FAPi PET中位SUVmax 9.6低于PSMA PET的14.5。

核心结论

  • 因CRPC中FAP表达水平低,FAPi PET显像的效用可能有限。
  • FAPi PET或许可在PSMA阴性CRPC(如小细胞癌)中进一步测试,但应评估其他分子影像方式作为替代选择。

研究设计与样本

  • 在116例CRPC肿瘤中采用免疫组化评估FAP表达,包括78例腺癌、11例小细胞癌和27例间变性癌。
  • 对54张转移性CRPC全切片进行手动评分与自动评分相关性分析。
  • 在CRPC组织微阵列芯(n=62)中评估配对FAP与PSMA染色,包括局部晚期CRPC(n=9)和转移性CRPC(n=53)。
  • FAP与PSMA阳性定义为免疫组化评分至少10。
  • 对纳入[68Ga]-FAPi-46显像试验(NCT04457232)的4例患者进行初步分析,探讨PSMA与FAPi PET显像和免疫组化的相关性。

主要发现

  • FAP手动评分与自动评分结果强相关。
  • CRPC中FAP表达总体显著低于PSMA表达(中位免疫评分14 vs 72,P<0.001)。
  • 不同组织学亚型CRPC的PSMA表达水平不同,而FAP表达水平相当。
  • 19例PSMA阴性肿瘤中11例(58%)显示FAP阳性。
  • 淋巴结转移灶FAP表达水平显著低于非淋巴结转移灶(P=0.021)。

关键数值与推荐

  • FAP与PSMA阳性定义为免疫组化评分至少10。
  • FAP表达低于PSMA:中位免疫评分14 vs 72(P<0.001)。
  • 19例PSMA阴性肿瘤中11例(58%)FAP阳性。
  • 淋巴结转移灶FAP表达低于非淋巴结转移灶(P=0.021)。
  • 肝转移灶较非肝病灶强FAP表达肿瘤富集(P=0.016)。

临床怎么用

  • 因CRPC中FAP表达低,FAPi PET显像的效用可能有限。
  • 作者认为,FAPi PET或许可在PSMA阴性CRPC(如小细胞癌)中进一步测试。
  • 作者认为,应评估其他分子影像方式作为替代选择。

局限性

  • FAPi PET与免疫组化相关性分析为对4例患者的初步分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA) is a theranostic target for metastatic prostate cancer (PCa). However, castration-resistant PCa (CRPC) may lose PSMA expression after systemic therapy. Fibroblast activation protein (FAP), expressed by carcinoma-associated fibroblasts in various cancer types, including PCa, has the potential to be an alternative target. In this study, we evaluated FAP expression in CRPC to assess its potential, using PSMA as a comparison. Methods: FAP expression was assessed using immunohistochemistry in 116 CRPC tumors: 78 adenocarcinomas, 11 small cell carcinomas, and 27 anaplastic carcinomas. Correlation analysis between manual scoring and automated scoring was performed on 54 whole-slide sections of metastatic CRPC. Paired FAP and PSMA stains were assessed in tissue microarray cores of CRPC (n = 62), consisting of locally advanced CRPC (n = 9) and metastatic CRPC (n = 53). FAP and PSMA positivity was defined by an immunohistochemistry score of at least 10. To explore the correlation of PSMA and FAP inhibitor (FAPi) PET imaging and immunohistochemistry, a preliminary analysis of 4 patients included in a [68Ga]-FAPi-46 imaging trial (NCT04457232) was conducted. Results: Manual and automated scoring of FAP yielded results with strong correlations. Overall, FAP expression in CRPC was notably lower than PSMA expression (median immunoscores, 14 vs. 72; P < 0.001). Different histologic subtypes of CRPC demonstrated distinct levels of PSMA expression, whereas their FAP expression levels were comparable. Among the 19 PSMA-negative tumors, 11 (58%) exhibited FAP positivity. FAP expression levels in lymph node metastases were significantly lower than those in nonnodal metastases (P = 0.021). Liver metastases showed significant enrichment of tumors with strong FAP expression compared with nonliver lesions (P = 0.016). In the 4 clinical trial patients, the biopsied metastatic lesions showed lower uptake on FAPi PET than on PSMA PET (median SUVmax, 9.6 vs. 14.5), consistent with FAP expression that was lower than PSMA expression in the corresponding tumor biopsy samples (median immunoscores, 30 vs. 160). Conclusion: Because of the low FAP expression levels in CRPC, the utility of FAPi PET imaging may be limited. Although FAPi PET imaging may be further tested in PSMA-negative CRPC, such as small cell carcinoma, other molecular imaging modalities should be evaluated as alternative choices.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Huang RR, Zuo C, Mona CE, et al. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. J Nucl Med. 2024. PMID: 39477498. doi:10.2967/jnumed.124.268037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。